ArticleEmerging infectious diseases2005
Neutralizing antibody response and SARS severity.
Article in Emerging infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2021Pooled it
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.Journal of medical virology · 2020Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2020Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.The Cochrane database of systematic reviews · 2020Pooled it
- Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection.Scientific reports · 2024Article
- Review
- SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.Frontiers in immunology · 2023Article
- Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.Oxford open immunology · 2023Review
- Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review.Medicina (Kaunas, Lithuania) · 2022Review
- The Association Between Clinical Severity and Incubation Period of SARS-CoV-2 Delta Variants: Retrospective Observational Study.JMIR public health and surveillance · 2022Observational
- Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19.Scientific reports · 2022Article
- Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis.Pathology · 2022Article
- The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection.International journal of molecular sciences · 2022Review
- Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?Infection · 2022Review
- Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.Journal of infection and public health · 2022Review
- The adaptation of SARS-CoV-2 to humans.Memorias do Instituto Oswaldo Cruz · 2022Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks. Patients with a longer illness showed a lower neutralizing antibody response than patients with a shorter illness duration (p = 0.008). When early responders were compared with most patients, who seroconverted on and after week 3 of illness, the small proportion (17.4%) of early responders (antibody detectable within 2 weeks) had a higher death rate (29.6% vs. 7.8%) (Fisher exact test, p = 0.004), had a shorter survival time of <2 weeks (Fisher exact test, p = 0.013), and were more likely to be > 60 years of age (Fisher exact test, p = 0.01). Our findings have implications for understanding the pathogenesis of SARS and for SARS vaccine research and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.